respiratory tract infection
Conditions
Interventions
Observers:Oral administration of 6mg/kg/time of D-ibuprofen, 3ml for individuals aged 6 months to 1 year, and 4ml/time for individuals aged 1 to 3 years
The daily dosage for children weighing less than 30kg should not exceed 300mg (25ml). Interval of 4-6 hours per use, medication should not exceed 4 times per day (28mg/kg).
control group:Oral ibuprofen (Meilin) 6mg/kg/time, 4ml for 1-3 years old
Sponsors
The Second Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
All
Age
6 Months to 3 Years
Inclusion criteria
Inclusion criteria: ? The diagnosis of upper or lower respiratory tract infection is when the axillary temperature of the child is = 38.5 ? and = 40.5 ?; ? The patient is a hospitalized child aged = 6 months and = 3 years old; ? Not using any antipyretic or analgesic drugs within 6 hours of fever; ? Not using glucocorticoids within 24 hours of fever; ? No serious underlying diseases, such as congenital heart disease, asthma, tumors, blood disorders, liver, liver, and kidney dysfunction; ? Voluntarily participating in this study, the child's legal guardian signed an informed consent form, and the process of obtaining informed consent complied with GCP regulations Ding.
Exclusion criteria
Exclusion criteria: ? Those who have taken ibuprofen oral suspension or used preparations containing ibuprofen within 6 hours of fever; ? Those who have taken acetaminophen suspension or preparations containing acetaminophen components within 6 hours of fever; ? Those who have used traditional Chinese medicine with antipyretic ingredients within 6 hours of fever or used glucocorticoid within 24 hours; ? Children with rash or chickenpox ? Children with severe malnutrition; ? Patients with heart failure or other organ dysfunction during medical treatment; ? Those who show signs of dehydration or high fever crisis during medical treatment; ? Individuals at risk of high fever within 6 months prior to seeking medical attention; ? Patients with active digestive ulcers at the time of consultation; ? Individuals with potential bleeding tendency or active bleeding symptoms during medical treatment; ? Individuals who have previously been allergic to ibuprofen or acetaminophen drugs; Previously taken aspirin and other nonsteroidal antibiotics Patients with asthma, rhinitis or urticaria induced by inflammatory drugs; ? Individuals with a history of kidney, liver, lung, endocrine, blood, or heart diseases prior to seeking medical attention, who have completed treatment for less than 6 months; ? Individuals with central nervous system abnormalities during medical treatment; ? Type 1 or type 2 diabetes patients who are not under control at present; ? Children with symptoms such as tuberculosis, sepsis, rheumatic fever, typhoid fever, local suppurative lesions, and prolonged fever; ? Due to other uncertain factors, the researcher has determined that they are not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in temperature change after 4 hours of administration; | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in Comfort Level;Gastrointestinal symptom evaluation;Safety indicators; | — |
Countries
china
Contacts
Public ContactYang Liu
The Second Affiliated Hospital of Nanchang University
Outcome results
None listed